加载中
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
前收盘价
US$7.21
−US$0.22 · -2.96%
盘后
US$7.21
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日内区间
当前US$7.21
52周区间
当前US$7.21
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
2
估值过高
情绪
43
多空交织
风险
55
风险偏高
动量
37
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日内区间
当前US$7.21
52周区间
当前US$7.21
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4826.6万 EUR | 1.56亿 EUR | 5399.7万 EUR | 1.73亿 EUR | 3476.3万 EUR |
| 毛利 | 4826.6万 EUR | 1.56亿 EUR | 5399.7万 EUR | 1.73亿 EUR | 3476.3万 EUR |
| 研究与开发 | 1.84亿 EUR | 1.48亿 EUR | 1.19亿 EUR | 1.07亿 EUR | 8757.4万 EUR |
| 销售、一般及管理费用 | 5118.4万 EUR | 4644.9万 EUR | 3819.8万 EUR | 3612.4万 EUR | 3380.8万 EUR |
| 营业费用 | 2.3亿 EUR | 1.94亿 EUR | 1.56亿 EUR | 1.43亿 EUR | 1.21亿 EUR |
| 利息收入 | 1717.9万 EUR | 2500.1万 EUR | 1384.5万 EUR | 247.6万 EUR | 13.3万 EUR |
| 利息支出 | 94.6万 EUR | 88.6万 EUR | 83.1万 EUR | 103.8万 EUR | 56.6万 EUR |
| 折旧和摊销 | 1240万 EUR | 1222.5万 EUR | 723.4万 EUR | 696.7万 EUR | 526万 EUR |
| 营业利润 | −1.82亿 EUR | −3861.5万 EUR | −1.02亿 EUR | 2995.4万 EUR | −8629.4万 EUR |
| 净利润 | −1.96亿 EUR | 1521.8万 EUR | −9464.9万 EUR | 2770.3万 EUR | −9333.5万 EUR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.00
上涨空间 135.78%报告持有此股票敞口的交易所交易基金。
State Street SPDR Portfolio Developed World ex-US ETFSPDW144.73万0.00%406.96亿 USD0.03%US$49.69-0.58%
ALPS Medical Breakthroughs ETFSBIO141.2万0.74%1.91亿 USD0.50%US$53.85-2.16%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP132.55万0.05%26.34亿 USD0.20%US$65.26-1.64%
Tema Oncology ETFCANC107.96万0.53%2.05亿 USD0.99%US$40.5781-0.50%
Fidelity Nasdaq Composite Index ETFONEQ45.19万—109.4亿 USD0.21%US$107.36-0.42%
State Street SPDR S&P International Small Cap ETFGWX41.54万0.05%9.15亿 USD0.40%US$45.26-0.66%
Virtus Biotech Clinical Trials ETFBBC25.14万0.60%4191.31万 USD0.65%US$43.13-2.30%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED24.49万0.74%3296.48万 USD0.44%US$33.6345-0.70%State Street SPDR Portfolio Developed World ex-US ETFSPDWALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P Kensho New Economies Composite ETFKOMPTema Oncology ETFCANCFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXVirtus Biotech Clinical Trials ETFBBCT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
